oral semaglutide novo Nordisk's weight-loss pill wins FDA approval Novo's Oral Wegovy: Dead-Cat Bounce

Current evidence suggests GLP-1 receptor agonists may have immunomodulatory properties, but no robust clinical trial data confirms they treat primary autoimmune diseases

This health technology enables, rather than corrects, and allows people to expand their lifestyles

Have recommend to family and friends

For patients who do not have insurance or whose insurance does not cover the cost of medication, our weight loss program in Burbank, California offers affordable self-pay options for accessing visits and medications

The analyses for this report were conducted using data from Californias Healthcare Payments Data (HPD) Program

"They can adjust their hormone output to support beta cells and maintain blood sugar balance." This flexibility could change how we think about treating type 2 diabetes, where beta cells in the pancreas can't make enough insulin to keep blood sugar at a healthy level